EUCTR2019-003829-18-GB进行中（未招募）1 期
A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of PNH
- •Clinically Evident EVH defined by:
- •- Anemia (Hgb =9.5 gram/deciliter) with absolute reticulocyte count =120 x 10^9/liter.
- •- At least 1 packed red blood cell or whole blood transfusion within 6 months prior to the start of the study.
- •Receiving a C5 inhibitor for at least 6 months prior to Day 1
- •Platelet count =30,000/microliters (µL)
- •Absolute neutrophil counts =750/µL.
- •Documentation of/or willingness to receive vaccinations and prophylactic antibiotics as required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 82
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •History of a major organ transplant or hematopoietic stem cell transplantation (HSCT).
- •Participants with known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and/or immunosuppressants.
- •Known or suspected complement deficiency.
- •Laboratory abnormalities at screening, including:
- •- Alkaline phosphatase >2 x upper limit of normal (ULN).
- •- Alanine aminotransferase >2 x ULN.
- •- Direct bilirubin >2 x ULN (unless due to EVH or documented Gilbert’s Syndrome.
- •Current evidence of biliary cholestasis.
- •Estimated glomerular filtration rate <30 milliliters/minute/1.73 meter squared and/or are on dialysis.
研究者
相似试验
进行中（未招募）
1 期
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH) (ALPHA)Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003829-18-GRAlexion Pharmaceuticals Inc.84
招募中
3 期
Pivotal study of danicopan as add-on therapy to a C5 inhibitor (eculizumab or ravulizumab) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have Clinically Evident EVHJPRN-jRCT2021210014Kamata Takeo84
进行中（未招募）
1 期
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH) (ALPHA)EUCTR2019-003829-18-DEAlexion Pharmaceuticals Inc.84
已完成
3 期
A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)Paroxysmal Nocturnal HemoglobinuriaPNH10038158NL-OMON55171Alexion Pharmaceuticals5
进行中（未招募）
1 期
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003829-18-ITALEXION PHARMACEUTICALS INCORPORATED84